Nant

NantWorks is a diversified healthcare and technology conglomerate founded by Dr. Patrick Soon-Shiong, focused on the convergence of molecular science, big data, and artificial intelligence to transform personalized medicine. The ecosystem operates through several key subsidiaries, including ImmunityBio, a publicly traded immunotherapy company, and NantHealth, a provider of healthcare IT and decision support solutions. NantWorks' primary biotech focus is 'orchestrated immunity,' which utilizes a multi-platform approach involving NK cells, T cells, and fusion proteins to treat cancer and infectious diseases. Its flagship product, Anktiva (N-803), received FDA approval in 2024 for the treatment of BCG-unresponsive non-muscle invasive bladder cancer. The company also maintains significant interests in molecular diagnostics, manufacturing, and high-performance computing to support its vision of data-driven healthcare.